Moreover, these patients more often developed complications (SOS (50% vs. 9%, p < 0.001), grade 2 and 3 GVHD (25% vs. 12.6% for grade 2 GVHD, 33.3% vs. 2.7% for grade 3 GVHD, respectively, p < 0.001), TMA (50% vs. 23.4%, p = 0.009), fever (87.5% vs. 46.8%, p < 0.001)), and had a significantly higher baseline level of CRP (83.3 (IQR: 22.9–218.6) vs. 7.8 (IQR: 2.7–46), p < 0.001). The gene discussed is CRP; the disease is graft versus host disease.